Evidence map›Paper›PMID 31557315›Full record

Trial reportClinical and experimental immunology2020

In-vivo assessment of T cell kinetics in individuals at risk for type 1 diabetes.

W Hao, H T Bahnson, C Speake, K Cerosaletti, C J Greenbaum

Open access · bronzeAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and experimental immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

W HaoDiabetes Clinical Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.ORCID 0000-0003-3917-2347
H T BahnsonDiabetes Clinical Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.
C SpeakeDiabetes Clinical Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.
K CerosalettiTranslational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.
C J GreenbaumDiabetes Clinical Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.
Benaroya Research InstituteVirginia Mason Medical Center · US

Funding

UCSF Trialnet: A Phase II Trial of Imatimib in New Onset Type I DiabetesU01DK061010 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GITELMAN, STEPHEN E · 2001 to 2018
$8.1M
Chicagoland Diabetes TrialNet Clinical CenterU01DK103153 · NIDDK · UNIVERSITY OF CHICAGO · PI PHILIPSON, LOUIS H. · 2014 to 2018
$1.4M
In Vivo Assessment of T Cell Kinetics in Individuals at Risk for Type 1 DiabetesDP3DK098217 · NIDDK · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI GREENBAUM, CARLA J · 2013 to 2013
$1.1M
NIDDK NIH HHS DP3 DK098217NIDDK NIH HHS U01 DK061010NIDDK NIH HHS U01 DK103153
6 · The paper itself

Abstract

We previously assessed the kinetics of T cell turnover in vivo by labeling cells with

Indexed as

Immunologic MemoryAdultCD8-Positive T-LymphocytesDiabetes Mellitus, Type 1FemaleHumansKineticsMaleRisk FactorsT-Lymphocytes, RegulatoryAutoantibodiesCD4 T cellsCD8 T cellsDeuterium labeled glucose (heavy glucose)Isotope labelingRegulatory T cellsT Cell kineticsType 1 diabetes

Identifiers

PMID31557315
PMCPMC6904646
OpenAlexW2975681793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.